INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Open-market purchaseVerified data

Keyes Jason A bought BLSM

Chief Financial Officer · BlossomHill Therapeutics, Inc. · Common Stock

Side
BUY
Value
$11K
Shares
700
Price
$16
Executed
Aug 10, 2026
Disclosed
Aug 10, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Aug 10 executedAug 10, 2026 disclosed

BLSM · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
46/ 100 · ELEVATED
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+13 / 25

    $11K reported value · new position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · BLSM

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    5
    LP
    Liptak Vincent PaulGeneral Counsel
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    22.7K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    13
    CJ
    Cui Jingrong JeanDirector, President and CEO, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    113.4K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    34
    LP
    Liptak Vincent PaulGeneral Counsel
    BLSMBlossomHill Therapeutics, Inc.
    Open-market purchase
    		BUY$40K
    2,500 sh
    		Aug 7, 2026Aug 10, 2026
    traded Aug 7, 2026
    		+3dSEC FORM 4

    Evidence

    30
    LP
    Liptak Vincent PaulGeneral Counsel
    BLSMBlossomHill Therapeutics, Inc.
    Open-market purchase
    		BUY$35K
    2,200 sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    AS
    Agrawal SundeepDirector
    BLSMBlossomHill Therapeutics, Inc.
    Grant or award
    		A—
    23.9K sh
    		Aug 6, 2026Aug 10, 2026
    traded Aug 6, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AS
    Agrawal SundeepDirector
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    578.5K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CJ
    Cui Jingrong JeanDirector, President and CEO, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    1.60M sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CJ
    Cui Jingrong JeanDirector, President and CEO, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    124.8K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CJ
    Cui Jingrong JeanDirector, President and CEO, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Grant or award
    		A—
    676.2K sh
    		Aug 6, 2026Aug 10, 2026
    traded Aug 6, 2026
    		+4dSEC FORM 4

    Evidence

    9
    CJ
    Cui Jingrong JeanDirector, President and CEO, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    1.60M sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CJ
    Cui Jingrong JeanDirector, President and CEO, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    113.4K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    CJ
    Cui Jingrong JeanDirector, President and CEO, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    124.8K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    LY
    Li YishanDirector, Executive Chairman, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    124.8K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    KA
    Keyes Jason AChief Financial Officer
    BLSMBlossomHill Therapeutics, Inc.
    Grant or award
    		A—
    56.7K sh
    		Aug 6, 2026Aug 10, 2026
    traded Aug 6, 2026
    		+4dSEC FORM 4

    Evidence

    9
    OR
    Oxnard Geoffrey RaymondChief Medical Officer
    BLSMBlossomHill Therapeutics, Inc.
    Grant or award
    		A—
    61.8K sh
    		Aug 6, 2026Aug 10, 2026
    traded Aug 6, 2026
    		+4dSEC FORM 4

    Evidence

    9
    AS
    Agrawal SundeepDirector
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    578.5K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    LY
    Li YishanDirector, Executive Chairman, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    1.60M sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    13
    LY
    Li YishanDirector, Executive Chairman, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    113.4K sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    9
    LY
    Li YishanDirector, Executive Chairman, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Grant or award
    		A—
    112.7K sh
    		Aug 6, 2026Aug 10, 2026
    traded Aug 6, 2026
    		+4dSEC FORM 4

    Evidence

    9
    LY
    Li YishanDirector, Executive Chairman, 10% Owner
    BLSMBlossomHill Therapeutics, Inc.
    Derivative conversion
    		C—
    1.60M sh
    		Aug 10, 2026Aug 10, 2026
    traded Aug 10, 2026
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001678152-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Aug 10, 2026
    Published
    Aug 10, 2026
    Ingested by INSIDER
    Nov 5, 02:24 UTC
    Last re-read
    Nov 5, 02:24 UTC

    Extracted facts

    Filer
    Keyes Jason A
    Role
    Chief Financial Officer
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    BlossomHill Therapeutics, Inc.
    Ticker
    BLSM
    Shares
    700
    Price per share
    $16
    Value
    $11,200
    Execution date (reported)
    Aug 10, 2026
    Owned after transaction
    700 shares
    Days from execution to publication
    0

    Calculation

    Value = shares × reported price per share

    • Shares: 700
    • Price: $16

    = $11,200

    What this establishes

    Keyes Jason A filed this Form 4 reporting a open-market purchase of BLSM on Aug 10, 2026. It became public on Aug 10, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Keyes Jason Acik:0001678152
    Issuer
    BlossomHill Therapeutics, Inc.cik:0001839970

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.